Cancer pain management and bone metastases: An update for the clinician

Breast Care

Volumn 7, Issue 2, 2012, Pages 113-120

  Schneider, Guido ^a,b   Voltz, Raymond ^a,b   Gaertner, Jan ^a,b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b University of Cologne   (Germany)

Author keywords

Bone metastases; Breast cancer; Cancer pain; Guidelines; Opioids; Palliative care; Palliative medicine

Indexed keywords

AMITRIPTYLINE; BISPHOSPHONIC ACID DERIVATIVE; CARBAMAZEPINE; DIPYRONE; FENTANYL; GABAPENTIN; GLUCOCORTICOID; METHADONE; NALOXONE; OPIATE; OXYCODONE; PREGABALIN;

ADVANCED CANCER; ANALGESIA; BONE METASTASIS; BONE PAIN; BREAKTHROUGH PAIN; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER STAGING; DRUG ABUSE; DRUG RELEASE; DRUG TOLERANCE; HUMAN; NEUROPATHIC PAIN; NOCICEPTION; NOCICEPTIVE PAIN; PHYSIOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOGENIC PAIN; REVIEW;

EID: 84861400563     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000338579     Document Type: Review

References (61)

1. Reed E, Simmonds P, Haviland J, Corner J: Quality of life and experience of care in women with metastatic breast cancer: a cross-sectional survey. J Pain Symptom Manage 2012;43:747-58.
2. Portenoy RK: Treatment of cancer pain. Lancet 2011;377:2236-47.
3. Benedetti C, Brock C, Cleeland C, Coyle N, Dub JE, et al.: NCCN Practice Guidelines for Cancer Pain. Oncology (Williston Park) 2000; 14(11A):135-50.
4. Krakowski I, Theobald S, Balp L, Bonnefoi MP, et al.: Summary version of the standards, options and recommendations for the use of analgesia for the treatment of nociceptive pain in adults with cancer (update 2002). Br J Cancer 2003;Suppl 1:S67-72.
5. Jost L, Roila F; ESMO Guidelines Working Group: Management of cancer pain: ESMO clinical recommendations. Ann Oncol 2008:19 Suppl 2: ii119-21.
6. Cormie PJ, Nairn M, Welsh J; Guideline Development Group: Control of pain in adults with cancer: summary of SIGN guidelines. BMJ 2008;337:a2154.
7. Dy SM, Asch SM, Naeim A, Sanati H, Walling A, Lorenz KA: Evidence-based standards for cancer pain management. J Clin Oncol 2008:26(23):3879-85.
8. Green E, Zwaal C, Beals C, Fitzgerald B, et al.: Cancer-related pain management: a report of evidence-based recommendations to guide practice. Clin J Pain 2010;26(6):449-62.
9. Trescot AM: Review of the role of opioids in cancer pain. J Natl Compr Canc Netw 2010:8(9):1087-94.
10. Azevedo S? Le? Ferreira K, Kimura M, Jacobsen Teixeira M: The WHO analgesic ladder for cancer pain control, twenty years of use. How much pain relief does one get from using it? Support Care Cancer 2006;14(11):1086-93.
11. Deandrea S, Montanari M, Moja L, Apolone G: Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 2008:19(12):1985-91.
12. Hjermstad MJ, Fainsinger R, Kaasa S; EuropeanPalliative Care Research Collaborative (EPCRC): Assessment and classification of cancer pain. Curr Opin Support Palliat Care 2009:3(1):24-30.
13. Jimenez-Andrade JM, Mantyh WG, Bloom AP et al.: Bone cancer pain. Ann N Y Acad Sci 2010:1198:173-81.
14. Bennett GJ: Pathophysiology and animal models of cancer-related painful peripheral neuropathy. Oncologist 2010:15 Suppl 2:9-12.
15. Caraceni A, Portenoy RK: An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain 1999;82(3):263-74.
16. van Oorschot B, Rades D, Schulze W, et al.: Palliative radiotherapy-new approaches. Semin Oncol 2011;38(3):443-9.
17. Chow E, Harris K, Fan G, et al.: Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol 2007;25(11):1423-36.
18. Roqu M, et al.: Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev 2011(7): CD003347.
19. Tanvetyanon T, Soares HP, Djulbegovic B, et al.: A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer. J Thorac Oncol 2007:2(12):1091-7.
20. Katz NP, Adams EH, Benneyan JC, Birnbaum HG, et al.: Foundations of opioid risk management. Clin J Pain 2007;23(2):103-18.
21. Savage SR, Joranson DE, Covington EC, et al.: Definitions related to the medical use of opioids: evolution towards universal agreement. J Pain Symptom Manage 2003;26(1):655-67.
22. Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, et al.: Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012;13(2):e58-e68.
23. Knotkova H, Fine PG, Portenoy RK: Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manage 2009;38(3):426-39.
24. Fine PG,Portenoy RK: Establishing ?best practices? for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage 2009;38(3):418-25.
25. Maltoni M, Scarpi E, Modonesi C, Passardi A, et al.: A validation study of the WHO analgesic ladder: a two-step vs three-step strategy. Support Care Cancer 2005;13(11):888-94.
26. King S, Forbes K, Hanks GW, et al.: A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project. Palliat Med 2011;25(5):525-52.
27. Gaertner J, Voltz R, Ostgathe C: Methadone: A closer look at the controversy. J Pain Symptom Manage 2008:36(2):e4-7.
28. Ostgathe C, Gaertner J, Nauck F, Voltz R: High dose levo-methadone treatment for cancer pain in a patient with a history of drug addiction. J Pain Symptom Manage 2008;35(3):229-31.
29. Sandoval JA, Furlan AD, Mailis-Gagnon A: Oral methadone for chronic noncancer pain: a systematic literature review of reasons for administration, prescription patterns, effectiveness, and side effects. Clin J Pain 2005:21(6):503-12.
30. Bruera E, Palmer JL, Bosnjak S, Rico MA, et al.: Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol 2004:22(1):185-92.
31. Mercadante S, Porzio G, Ferrera P, Fulfaro F, et al.: Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain 2008;12(8):1040-6.
32. Bryson J, Tamber A, Seccareccia D, et al.: Methadone for treatment of cancer pain. Curr Oncol Rep 2006;8(4):282-8.
33. Modesto-Lowe V, Brooks D, Petry N: Methadone deaths: risk factors in pain and addicted populations. J Gen Intern Med 2010;25(4):305-9.
34. Gaertner J, Ruberg K, Schlesiger G, et al.: Drug interactions in palliative care-it?s more than cytochrome P450. Palliat Med 2011 Jul 7. [Epub ahead of print].
35. Dunlop W, Uhl R, Khan I, et al.: Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis. J Med Econ 2012;15(3):564-75.
36. Hoy SM: Tapentadol extended release: in adults with chronic pain. Drugs 2012;72(3):375-93.
37. Ahmedzai SH, Nauck F, Bar-Sela G, et al.: A randomized, double-blind, active-controlled, doubledummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolongedrelease tablets in patients with moderate/severe, chronic cancer pain. Palliat Med 2012;26(1):50-60.
38. Tassinari D, Drudi F, Rosati M, et al.: Transdermal opioids as front line treatment of moderate to severe cancer pain: a systemic review. Palliat Med 2011;25(5):478-87.
39. Wilcock A, Jacob JK, Charlesworth S, et al.: Drugs given by a syringe driver: a prospective multicentre survey of palliative care services in the UK. Palliat Med 2006;20(7):661-4.
40. Akram G, Bennie M, McKellar S, et al.: Effective Delivery of Pharmaceutical Palliative Care: Challenges in the Community Pharmacy Setting. J Palliat Med 2012 ;15(3):317-21.
41. Menahem S, Shvartzman P: Continuous subcutaneous delivery of medications for home care palliative patients-using an infusion set or a pump? Support Care Cancer 2010;18(9):1165-70.
42. Sloan PA: Neuraxial pain relief for intractable cancer pain. Curr Pain Headache Rep 2007;11(4):283-9.
43. Smith TJ, Staats PS, Deer T, et al.: Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 2002;20(19):4040-9.
44. Elsner F, Radbruch L, Loick G, et al.: Intravenous versus subcutaneous morphine titration in patients with persisting exacerbation of cancer pain. J Palliat Med 2005;8(4):743-50.
45. Gaertner J,Voltz J: Breakthrough pain. J Palliat Med 2010;13(3):345.
46. Gaertner J,Voltz R: The cancer pain management plan. J Palliat Med 2010;13(1):95-6.
47. Zeppetella G: Impact and management of breakthrough pain in cancer. Curr Opin Support Palliat Care 2009;3(1):1-6.
48. McNicol E, et al.: NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev 2005;CD005180.
49. Chen YF, Jobanputra P, Barton P, et al.: Cyclooxygenase-selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2008;12(11):1-278, iii.
50. Moore RA, Derry S, McQuay HJ: Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskelet Disord 2007;8:73.
51. Costa L, Major PP. Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 2009,6(3):163-74.
52. Bennett MI, Rayment C, Hjermstad M, et al.: Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review. Pain 2012;153(2):359-65.
53. Ong CK, Forbes D: Embracing Cicely Saunders?s concept of total pain. BMJ 2005;331(7516):576.
54. Strohbuecker B, Gaertner J, Stock S: Informing severely ill patients: needs, shortcomings and strategies for improvement. Breast Care (Basel) 2011;6(1):8-13.
55. Gaertner J, Zindel S, Stock S, Voltz R: Talking about life-threatening illness. JPM Patient Information. J Palliat Med 2010;13(11):1396-7.
56. Kwekkeboom KL, Cherwin CH, Lee JW, et al.: Mind-body treatments for the pain-fatigue-sleep disturbance symptom cluster in persons with cancer. J Pain Symptom Manage 2010;39(1):126-38.
57. Bardia A, Barton DL, Prokop LJ, et al.: Efficacy of complementary and alternative medicine therapies in relieving cancer pain: a systematic review. J Clin Oncol 2006;24(34):5457-64.
58. Cassileth BR, Keefe FJ: Integrative and behavioral approaches to the treatment of cancer-related neuropathic pain. Oncologist 2010;15 Suppl 2:19-23.
59. Baile WF, Buckman R, Lenzi R, et al.: SPIKESA six-step protocol for delivering bad news: application to the patient with cancer. Oncologist 2000;5(4):302-11.
60. Johnson C, Fitzsimmons D, Gilbert J, et al.: Development of the European Organisation for Research and Treatment of Cancer quality of life questionnaire module for older people with cancer: The EORTC QLQ-ELD15. Eur J Cancer 2010;46(12):2242-52.
61. Ferris FD, Bruera E, Cherny N, Cummings C, et al.: Palliative cancer care a decade later: accomplishments, the need, next steps-from the American Society of Clinical Oncology. J Clin Oncol 2009;27(18):3052-8.